SCHEMBL3088869

SCHEMBL3088869

CC(=O)N1CCC(O)(C(=O)c2ccc(Cl)cc2F)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
OPRL1 P41146 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
FASN P49327 2/20 0.42
HPGD P15428 1/20 0.40
SPR P35270 1/20 0.39
P2RX7 Q99572 1/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
CPS1 P31327 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
CLK1 P49759 1/20 0.38
DRD2 P14416 1/20 0.37
NOTUM Q6P988 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9866909 0.81 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ANPC1MAPK1
SCHEMBL9867176 0.81 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AHPGDMAPK1
SCHEMBL5803990 0.79 DRD2 (0.42) FASNP2RX7NPC1CYP11B1CYP11B2
SCHEMBL10395236 0.75 CPS1 (0.55) ALDH1A1OPRL1MEN1KMT2ACPS1
SCHEMBL25334618 0.72 NPC1 (0.50) ALDH1A1FASNSPRP2RX7NPC1
SCHEMBL29392929 0.69 MAOB (0.58) ALDH1A1KMT2ANPC1CYP11B1CYP11B2
SCHEMBL325429 0.69 MAOB (0.58) ALDH1A1KMT2ANPC1CYP11B1CYP11B2
SCHEMBL26922704 0.69 USP30 (0.54)
SCHEMBL13923623 0.68 MEN1 (0.61) ALDH1A1OPRL1MEN1KMT2AHPGD
SCHEMBL21383779 0.68 CES2 (0.46) ALDH1A1OPRL1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399455-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-03-19 US disclosed
US-8399455-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-03-19 US disclosed
US-8399455-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-03-19 US disclosed
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7635698-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7635698-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7635698-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-20060189628-A1 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS ACKR3, CCR5, CXCR2 ALDH1A1 1889/4885OPRL1 80/4885MEN1 2336/4885
US-20060189628-A1 Compounds useful as chemokine receptor antagonists ACKR3, CCR5, CXCR2 ALDH1A1 1889/4885OPRL1 80/4885MEN1 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.